MX372991B - Una formulacion en aerosol en suspension que comprende fumarato de fermoterol dihidratado y propionato de fluticasona suspendido en propelente de hpa y un agente humectante. - Google Patents
Una formulacion en aerosol en suspension que comprende fumarato de fermoterol dihidratado y propionato de fluticasona suspendido en propelente de hpa y un agente humectante.Info
- Publication number
- MX372991B MX372991B MX2012004338A MX2012004338A MX372991B MX 372991 B MX372991 B MX 372991B MX 2012004338 A MX2012004338 A MX 2012004338A MX 2012004338 A MX2012004338 A MX 2012004338A MX 372991 B MX372991 B MX 372991B
- Authority
- MX
- Mexico
- Prior art keywords
- propellant
- fluticasone propionate
- fermoterol
- humecting
- hpa
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000000443 aerosol Substances 0.000 title abstract 2
- 229960000289 fluticasone propionate Drugs 0.000 title abstract 2
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 title abstract 2
- 239000003380 propellant Substances 0.000 title abstract 2
- 239000000725 suspension Substances 0.000 title abstract 2
- NWLPAIVRIWBEIT-SEPHDYHBSA-N (e)-but-2-enedioic acid;dihydrate Chemical compound O.O.OC(=O)\C=C\C(O)=O NWLPAIVRIWBEIT-SEPHDYHBSA-N 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 239000002245 particle Substances 0.000 abstract 2
- RATSWNOMCHFQGJ-TUYNVFRMSA-N (e)-but-2-enedioic acid;n-[2-hydroxy-5-[(1s)-1-hydroxy-2-[[(2s)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide;dihydrate Chemical compound O.O.OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 RATSWNOMCHFQGJ-TUYNVFRMSA-N 0.000 abstract 1
- 230000008021 deposition Effects 0.000 abstract 1
- 229960003610 formoterol fumarate dihydrate Drugs 0.000 abstract 1
- 229940071648 metered dose inhaler Drugs 0.000 abstract 1
- 239000000080 wetting agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0918150.4A GB0918150D0 (en) | 2009-10-16 | 2009-10-16 | Improved formulations |
| PCT/EP2010/065569 WO2011045429A1 (en) | 2009-10-16 | 2010-10-15 | Improved formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2012004338A MX2012004338A (es) | 2012-08-01 |
| MX372991B true MX372991B (es) | 2020-06-18 |
Family
ID=41462451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012004338A MX372991B (es) | 2009-10-16 | 2010-10-15 | Una formulacion en aerosol en suspension que comprende fumarato de fermoterol dihidratado y propionato de fluticasona suspendido en propelente de hpa y un agente humectante. |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US20120263766A1 (https=) |
| EP (2) | EP3811928A1 (https=) |
| JP (2) | JP5818801B2 (https=) |
| CN (1) | CN102573791B (https=) |
| AU (1) | AU2010305695B2 (https=) |
| BR (1) | BR112012008969B1 (https=) |
| CA (1) | CA2776845C (https=) |
| CL (1) | CL2012000948A1 (https=) |
| CY (1) | CY1123918T1 (https=) |
| DK (1) | DK2488157T3 (https=) |
| ES (1) | ES2859629T3 (https=) |
| GB (1) | GB0918150D0 (https=) |
| HR (1) | HRP20210379T1 (https=) |
| HU (1) | HUE054030T2 (https=) |
| IL (2) | IL219162A0 (https=) |
| LT (1) | LT2488157T (https=) |
| MX (1) | MX372991B (https=) |
| NZ (1) | NZ599900A (https=) |
| PL (1) | PL2488157T3 (https=) |
| PT (1) | PT2488157T (https=) |
| RS (1) | RS61430B1 (https=) |
| SI (1) | SI2488157T1 (https=) |
| SM (1) | SMT202100150T1 (https=) |
| WO (1) | WO2011045429A1 (https=) |
| ZA (1) | ZA201202595B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1372608E (pt) * | 2001-03-30 | 2008-01-04 | Jagotec Ag | Formulações de aerossol médicas |
| GB0323684D0 (en) | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
| GB0918149D0 (en) * | 2009-10-16 | 2009-12-02 | Jagotec Ag | Improved medicinal aerosol formulation |
| GB0918150D0 (en) * | 2009-10-16 | 2009-12-02 | Jagotec Ag | Improved formulations |
| EP2819669B1 (de) * | 2012-02-28 | 2021-04-21 | Boehringer Ingelheim International GmbH | Neue treibgashaltige tiotropium-formulierung |
| IN2014MN02133A (https=) * | 2012-04-11 | 2015-10-09 | Cipla Ltd | |
| GB201321712D0 (en) * | 2013-12-09 | 2014-01-22 | Pharmachemie Bv | Dry Powder Inhaler |
| CN105963282B (zh) * | 2016-05-04 | 2019-04-19 | 四川普锐特医药科技有限责任公司 | 一种医用定量吸入气雾剂 |
| WO2018059390A1 (zh) * | 2016-09-29 | 2018-04-05 | 广东东阳光药业有限公司 | 药物组合物 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596260B1 (en) | 1993-08-27 | 2003-07-22 | Novartis Corporation | Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol |
| TR199701169T1 (xx) | 1995-04-14 | 1998-03-21 | Glaxo Wellcome Inc. | Salmeterol i�in �l��lm�� doz inhaleri. |
| HU219900B (hu) | 1995-04-14 | 2001-09-28 | Glaxo Wellcome Inc. | Mért dózist adagoló inhalálóberendezés |
| JPH101442A (ja) * | 1996-06-12 | 1998-01-06 | Taisho Pharmaceut Co Ltd | 鼻炎用点鼻薬 |
| WO1998041193A1 (en) * | 1997-03-20 | 1998-09-24 | Schering Corporation | Preparation of powder agglomerates |
| GB9903759D0 (en) * | 1999-02-18 | 1999-04-14 | Novartis Ag | Organic compounds |
| AU2000250701B2 (en) * | 2000-05-22 | 2004-07-01 | Chiesi Farmaceutici S.P.A. | Stable pharmaceutical solution formulations for pressurised metered dose inhalers |
| US20060257324A1 (en) * | 2000-05-22 | 2006-11-16 | Chiesi Farmaceutici S.P.A. | Pharmaceutical solution formulations for pressurised metered dose inhalers |
| WO2002024552A2 (en) | 2000-09-18 | 2002-03-28 | Glaxo Group Limited | Coated can for a metered dose inhaler |
| ES2260299T3 (es) * | 2000-10-09 | 2006-11-01 | 3M Innovative Properties Company | Formulaciones medicinales en aerosol. |
| PT1372608E (pt) * | 2001-03-30 | 2008-01-04 | Jagotec Ag | Formulações de aerossol médicas |
| US6667344B2 (en) * | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
| GB0201400D0 (en) * | 2002-01-22 | 2002-03-13 | Glaxo Group Ltd | Novel apparatus and process |
| WO2004019985A1 (en) * | 2002-08-29 | 2004-03-11 | Cipla Ltd | Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids |
| GB0323684D0 (en) * | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
| GB0327727D0 (en) * | 2003-11-28 | 2003-12-31 | Quadrant Drug Delivery Ltd | Viral microparticles |
| GB0410399D0 (en) * | 2004-05-10 | 2004-06-16 | Arakis Ltd | The treatment of respiratory disease |
| GB0918150D0 (en) * | 2009-10-16 | 2009-12-02 | Jagotec Ag | Improved formulations |
-
2009
- 2009-10-16 GB GBGB0918150.4A patent/GB0918150D0/en not_active Ceased
-
2010
- 2010-10-15 EP EP20213235.3A patent/EP3811928A1/en not_active Withdrawn
- 2010-10-15 SM SM20210150T patent/SMT202100150T1/it unknown
- 2010-10-15 BR BR112012008969-2A patent/BR112012008969B1/pt active IP Right Grant
- 2010-10-15 MX MX2012004338A patent/MX372991B/es active IP Right Grant
- 2010-10-15 HR HRP20210379TT patent/HRP20210379T1/hr unknown
- 2010-10-15 HU HUE10768760A patent/HUE054030T2/hu unknown
- 2010-10-15 EP EP10768760.0A patent/EP2488157B1/en active Active
- 2010-10-15 PT PT107687600T patent/PT2488157T/pt unknown
- 2010-10-15 US US13/502,097 patent/US20120263766A1/en not_active Abandoned
- 2010-10-15 NZ NZ599900A patent/NZ599900A/en unknown
- 2010-10-15 CN CN201080046305.6A patent/CN102573791B/zh active Active
- 2010-10-15 RS RS20210159A patent/RS61430B1/sr unknown
- 2010-10-15 ES ES10768760T patent/ES2859629T3/es active Active
- 2010-10-15 CA CA2776845A patent/CA2776845C/en active Active
- 2010-10-15 AU AU2010305695A patent/AU2010305695B2/en active Active
- 2010-10-15 SI SI201032050T patent/SI2488157T1/sl unknown
- 2010-10-15 PL PL10768760T patent/PL2488157T3/pl unknown
- 2010-10-15 LT LTEP10768760.0T patent/LT2488157T/lt unknown
- 2010-10-15 WO PCT/EP2010/065569 patent/WO2011045429A1/en not_active Ceased
- 2010-10-15 DK DK10768760.0T patent/DK2488157T3/da active
- 2010-10-15 JP JP2012533648A patent/JP5818801B2/ja active Active
-
2012
- 2012-04-11 ZA ZA2012/02595A patent/ZA201202595B/en unknown
- 2012-04-13 CL CL2012000948A patent/CL2012000948A1/es unknown
- 2012-04-15 IL IL219162A patent/IL219162A0/en unknown
-
2015
- 2015-09-29 JP JP2015191177A patent/JP2016040286A/ja active Pending
-
2017
- 2017-03-21 US US15/464,879 patent/US20180296468A2/en not_active Abandoned
-
2019
- 2019-09-15 IL IL26936919A patent/IL269369A/en unknown
-
2021
- 2021-03-05 CY CY20211100190T patent/CY1123918T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX372991B (es) | Una formulacion en aerosol en suspension que comprende fumarato de fermoterol dihidratado y propionato de fluticasona suspendido en propelente de hpa y un agente humectante. | |
| PH12017500778A1 (en) | COMPOSITIONS, METHODS and SYSTEMS FOR RESPIRATORY DELIVERY OF TWO OR MORE ACTIVE AGENTS | |
| GB201210580D0 (en) | Metered dose dispensing valve | |
| MX2010003935A (es) | Suministro de farmaco por inhalacion. | |
| EA201290375A1 (ru) | Комбинированная терапия copd | |
| GB201118188D0 (en) | Manufacture of medicinal aerosol canisters | |
| PH12013502270A1 (en) | Compositions, methods & systems for respiratory delivery of two or more active agents | |
| CL2015002857A1 (es) | Contenedor recargable a presión con una válvula de escape. | |
| WO2015054124A3 (en) | Dry powder inhaler | |
| UY30139A1 (es) | Formulacion farmaceuica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva | |
| MX2014004279A (es) | Composiciones que comprenden sulfato de salbutamol. | |
| PH12014502746A1 (en) | Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same | |
| MX2014004364A (es) | Composiciones que comprenden sulfato de salbutamol. | |
| HK1221653A1 (zh) | 用於呼吸递送三种或更多种活性剂的组合物、方法和系统 | |
| JP2014530231A5 (https=) | ||
| MX370890B (es) | Composición que comprende sulfato de salbutamol. | |
| MX2015015132A (es) | Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen. | |
| MX2020003436A (es) | Inhalador de polvo seco y metodo de uso. | |
| MX383344B (es) | Inhalador de polvo seco con propionato de fluticasona y xinafoato de salmeterol. | |
| WO2013104892A8 (en) | Application of high dose compounds via inhalation | |
| CL2014003211A1 (es) | Composicion farmaceutica para inhalacion que comprende aclidinio, con lactosa, que proporciona una dosis de 322 ug de base libre y aprox 140 ug de bromuro de aclidinio; un metodo para tratar una afeccion respiratoria seleccionada de asma y epoc; uso de la composicion; y un dispositivo inhalador de polvo seco calibrado que la comprende | |
| AR067459A1 (es) | Inhalador | |
| PT3519024T (pt) | Nebulizador, em particular inalador, para a nebulização de uma substância ativa líquida para um aerossol, bem como um processo correspondente | |
| BRPI0417154A (pt) | inalador, espaçador para uso com um inalador e método de introduzir uma droga a partir de um inalador em um espaçador | |
| PH12014500440A1 (en) | Method for preparing metered dose sprayed inhaler for treating respiratory disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GD | Licence granted | ||
| GD | Licence granted | ||
| FG | Grant or registration |